

07-26-04

IFW



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

EXPRESS MAIL NO. EV 182094747US

Application No.	10/723,520
Filing Date	November 26, 2003
First Named Inventor	Mark R. ANDERSEN
Examiner Name	Not yet assigned
Group Art Unit	1637
Confirmation No.	8934

Total Number of Pages in This Submission	5	Attorney Docket No.	A-71902/AMP/JFB (470438-61)
--	---	---------------------	--------------------------------

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Form PTO/SB/08A-B (2 pgs.); sixteen (16) references; and self-addressed stamped Postcard.
<input checked="" type="checkbox"/> Information Disclosure Statement (2 pgs.)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, No. of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	John F. Brady, Ph.D., Reg. No. 39,118 DORSEY & WHITNEY LLP 4 Embarcadero Center, Suite 3400 San Francisco, CA 94111 Telephone: 650-494-8700	Customer Number 32940
Signature		
Date	July 22, 2004	

PATENT

Attorney Docket No. A-71902/AMP/JFB
Dorsey File No. 470438-61

EXPRESS MAIL NO. EV 182094747US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

ANDERSEN et al.

U.S. Serial No.: 10/723,520

Filing Date: November 26, 2003

Confirmation No. 8934

For: *Multiplex Amplification of
Polynucleotides*

Examiner: Not yet assigned

Art Unit: 1637

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A-B. In accordance with 1273 Off. Gaz. Pat. Off. 1, 8/5/2003, no copies of U.S. patents and U.S. published applications are enclosed. Copies of all other references are enclosed.

None of the foregoing references is believed to disclose the invention as claimed. Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a

U.S. Serial No.: 10/723,520
Filing Date: November 26, 2003

first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required.


While no fee is believed to be due, if this belief is in error the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 470438-00061 [A-71902/AMP/JFB]).

Please direct any calls in connection with this application to the undersigned at (650) 494-8700.

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: 7-22-04


BY:


John F. Brady, Reg. No. 39,118

Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (650) 494-8700
Facsimile: (650) 494-8771

Attachments:

Form PTO/SB/8A-B (2 pgs.)
Sixteen (16) References



 Substitute for form 1449A/PTO (Modified)		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>		Application Number	10/723,520	
		Filing Date	November 26, 2003	
		First Named Inventor	Mark R. ANDERSEN	
		Art Unit	1637	
		Examiner Name	Not yet assigned	
Sheet	1	of	2	Attorney Docket Number
				A-71902/AMP/JFB (470438-61)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

16 if possible. * Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/723,520
Filing Date	November 26, 2003
First Named Inventor	Mark R. ANDERSEN
Group Art Unit	1637
Examiner Name	Not yet assigned

Sheet 2 of 2 Attorney Docket Number A-71902/AMP/JFB (470438-61)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
,	C1	Assays-by-Design SM Service [online], [retrieved on 2003-05-13], Retrieved from the Applied Biosystems using Internet <URL: http://www.applied biosystems.com/products/productdetail.cfm?prod_id=761>.	
-	C2	Assays-on-Demand TM Gene Expression Products [online], [retrieved on 2003-05-13], Retrieved from the Applied Biosystems using Internet <http://www.applied biosystems.com/products/productdetail.cfm?prod_id=1101>.	
-	C3	Assays-on-Demand TM SNP Genotyping Products [online], [retrieved on 2003-05-13], Retrieved from the Applied Biosystems using Internet <http://www.applied biosystems.com/products/productdetail.cfm?prod_id=1141>.	
	C4	User Bulletin #2: ABI Prism 7700 Sequence Detection System. Subject: Relative Quantitation of Gene Expression, Datasheet. Applied Biosystems, 1997 (updated 10/2001).	
	C5	CHAMBERLAIN, J.S., "Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification", <i>Nucleic Acids Research</i> , 1988, 16(23): 11141-11156.	
	C6	DOLGANOV, G., "A Novel Method of Gene Transcript Profiling in Airway Biopsy Homogenates Reveals Increased Expression of a Na ⁺ -K ⁺ -Cl ⁻ Cotransporter (NKCC1) in Asthmatic Subjects", 2001, 11:1473-1483.	
	C7	EDWARDS, M., et al., "Multiplex PCR: Advantages, Development, and Applications", <i>PCR Methods and Applications</i> , Cold Spring Harbor Laboratory, 1994, pp. S65-S75.	
<	C8	EXNER, M., et al., "Sensitivity of multiplex real-time PCR reactions, using the LightCycler and the ABI PRISM 7700 Sequence Detection System, is dependent on the concentration of the DNA polymerase", <i>Mol. Cell Probes</i> , October 2002, 16:351-357.	
	C9	HENEGARIU, O., "Multiplex PCR: Critical Parameters and Step-by-Step Protocol", <i>BioTechniques</i> , September 1997, 23:504-511.	
	C10	JAYARAMAN, K., et al., "A PCR-Mediated Gene Synthesis Strategy Involving the Assembly of Oligonucleotides Representing Only One of the Strands", <i>BioTechniques</i> , 1992, 12(3): 392-398.	
	C11	LI, D., et al., "Multiplex co-amplification of 24 retinoblastoma gene exons after pre-amplification by long-distance PCR", <i>Nucleic Acids Research</i> , 1996, 24(3): 538-539.	
-	C12	PEIRSON, S.N., "Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis", <i>Nucleic Acids Res.</i> , 2003, 31(14):e73.	
	C13	SHUBER, A., et al., "A Simplified Procedure for Developing Multiplex PCRs", <i>Genome Research</i> , 1995, 5: 488-493.	
<	C14	TICHOPAD, A., et al., "Standardized determination of real-time PCR efficiency from a single reaction set-up", <i>Nucleic Acids Res.</i> , 2003, 31:e122.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[]